SCHEMBL15422733

SCHEMBL15422733

CC(C)n1cnc2c(N[C@@](C)(Cc3ccc(O)cc3)C(=O)O)nc(-c3cccnc3)nc21

nearest known ligand 0.42

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ CDK2 P24941 15/20 0.42
▸ CCNA2 P20248 7/20 0.42
▸ CCNA1 P78396 7/20 0.42
▸ CDK5 Q00535 7/20 0.42
▸ CDK5R1 Q15078 7/20 0.42
▸ DYRK1A Q13627 5/20 0.42
▸ CDK1 P06493 9/20 0.42
▸ CCNB1 P14635 9/20 0.42
▸ CCNE1 P24864 8/20 0.42
▸ CDK4 P11802 6/20 0.42
▸ CCND1 P24385 6/20 0.42
▸ MAPK1 P28482 6/20 0.42
▸ CDK7 P50613 6/20 0.42
▸ CCNH P51946 6/20 0.42
▸ CDK9 P50750 4/20 0.42
▸ CCNT1 O60563 2/20 0.42
▸ AHR P35869 1/20 0.42
▸ CCNE2 O96020 2/20 0.41
▸ CCNB2 O95067 3/20 0.41
▸ CCNB3 Q8WWL7 3/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3242817 0.82 ITGB1 (0.46) CDK2CCNA2CCNA1CDK5CDK5R1
SCHEMBL2314283 0.82 CDK2 (0.47) CDK2CCNA2CCNA1CDK5CDK5R1
SCHEMBL2312171 0.80 CDK2 (0.46) CDK2CCNA2CCNA1CDK5CDK5R1
SCHEMBL2317564 0.80 AHR (0.62) CDK2CCNA2CCNA1CDK5CDK5R1
SCHEMBL2313974 0.80 CDK1 (0.45) CDK2CCNA2CCNA1CDK5CDK5R1
SCHEMBL30315264 0.80 CDK1 (0.45) CDK2CCNA2CCNA1CDK5CDK5R1
SCHEMBL2313988 0.77 CDK2 (0.42) CDK2CCNA2CCNA1CDK5CDK5R1
SCHEMBL2311219 0.76 CDK2 (0.46) CDK2CCNA2CCNA1CDK5CDK5R1
SCHEMBL2312183 0.75 AHR (0.43) CDK2CCNA2CCNA1CDK5CDK5R1
SCHEMBL2315248 0.75 CDK2 (0.41) CDK2CCNA2CCNA1CDK5CDK5R1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-9567569-B2 Methods of culturing and expanding mesenchymal stem cells GAMIDA CELL LTD. (IL) 2017-02-14 — — US disclosed
US-20140023623-A1 Methods of Culturing and Expanding Mesenchymal Stem Cells and Isolated Cell Populations Generated Thereby GAMIDA CELL INC. 2014-01-23 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20140023623-A1 Methods of Culturing and Expanding Mesenchymal Stem Cells and Isolated Cell Populations Generated Thereby AHR, HGF, MTNR1A CDK2 2032/4885CCNA2 1777/4885CCNA1 2187/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback